Celdoxome Pegylated Liposomal: Uses, Dosage & Side Effects
A pegylated liposomal doxorubicin formulation used to treat breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma with reduced cardiotoxicity
Celdoxome pegylated liposomal is a cancer treatment containing doxorubicin hydrochloride encapsulated in pegylated liposomes (tiny fat-coated particles with a polyethylene glycol coating). This advanced drug delivery system allows doxorubicin to circulate longer in the bloodstream and accumulate preferentially in tumor tissue, improving anticancer efficacy while significantly reducing the risk of heart damage and other systemic side effects compared with conventional doxorubicin. It is used to treat metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma (in combination with bortezomib), and AIDS-related Kaposi sarcoma. Celdoxome pegylated liposomal is administered as an intravenous infusion in hospital settings and requires a prescription.
Quick Facts: Celdoxome Pegylated Liposomal
Key Takeaways
- Celdoxome pegylated liposomal contains doxorubicin enclosed in pegylated liposomes, allowing targeted delivery to tumors with significantly reduced cardiotoxicity compared with conventional doxorubicin formulations.
- It is approved for metastatic breast cancer (in patients at increased cardiac risk), advanced ovarian cancer (after platinum-based chemotherapy failure), progressive multiple myeloma (with bortezomib), and AIDS-related Kaposi sarcoma.
- Hand-foot syndrome (palmar-plantar erythrodysesthesia) is the most characteristic side effect; patients should be counseled on skin care measures and dose modifications may be necessary for severe cases.
- Cardiac monitoring with echocardiography or MUGA scan is required before and during treatment, as cumulative doxorubicin exposure increases the risk of congestive heart failure.
- This formulation must NOT be used interchangeably with other doxorubicin products; the unique pharmacokinetic profile of pegylated liposomal doxorubicin requires specific dosing regimens distinct from conventional doxorubicin.
What Is Celdoxome Pegylated Liposomal and What Is It Used For?
Celdoxome pegylated liposomal contains the active substance doxorubicin hydrochloride, one of the most widely used and effective anticancer drugs in clinical oncology. Doxorubicin belongs to the anthracycline class of chemotherapy agents and works primarily by intercalating into the DNA double helix and inhibiting the enzyme topoisomerase II. This dual mechanism disrupts DNA replication and transcription, leading to cell death in rapidly dividing cancer cells. The drug has been a cornerstone of cancer treatment for decades, but its clinical utility with conventional formulations has been limited by dose-dependent cardiotoxicity that can lead to irreversible congestive heart failure.
The innovation behind Celdoxome pegylated liposomal lies in its advanced drug delivery system. Doxorubicin is encapsulated within small unilamellar liposomes — nanoscale vesicles made from phospholipid bilayers — that are coated with polyethylene glycol (PEG) on their surface. This PEG coating, often referred to as “stealth” technology, dramatically reduces recognition and clearance by the body’s immune system (the reticuloendothelial system). As a result, the pegylated liposomes circulate in the bloodstream for much longer than conventional doxorubicin, with a plasma half-life of approximately 55 hours compared with roughly 5 hours for the non-liposomal form.
The prolonged circulation time allows the pegylated liposomes to accumulate preferentially in tumor tissue through a phenomenon known as the enhanced permeability and retention (EPR) effect. Tumors typically have leaky blood vessels with gaps large enough for the liposomes (approximately 100 nm in diameter) to pass through, while healthy tissues have tighter vascular walls that largely exclude liposomes. Once the liposomes accumulate in the tumor, doxorubicin is gradually released and enters the cancer cells. This preferential delivery means higher drug concentrations at the tumor site and lower exposure of healthy organs, particularly the heart, to free doxorubicin.
Celdoxome pegylated liposomal is approved by the European Medicines Agency (EMA) and regulatory authorities worldwide for the following therapeutic indications:
- Metastatic breast cancer: Used as monotherapy in patients where there is an increased cardiac risk. Pegylated liposomal doxorubicin provides comparable anticancer activity to conventional anthracycline regimens with a significantly lower incidence of cardiotoxicity, making it particularly suitable for patients with pre-existing cardiac conditions, prior anthracycline exposure, or advanced age. Clinical trials have demonstrated non-inferior efficacy with markedly improved cardiac safety profiles.
- Advanced ovarian cancer: Used in patients whose disease has progressed or recurred after platinum-based first-line chemotherapy. Pegylated liposomal doxorubicin has become a standard treatment option for platinum-resistant and platinum-sensitive recurrent ovarian cancer, with randomized trials demonstrating favorable efficacy-to-toxicity ratios compared with alternative chemotherapy regimens.
- Progressive multiple myeloma: Used in combination with the proteasome inhibitor bortezomib in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation. The combination has demonstrated significant improvement in time to disease progression compared with bortezomib alone in large randomized clinical trials.
- AIDS-related Kaposi sarcoma: Used in patients with advanced disease, significant mucocutaneous or visceral involvement, or Kaposi sarcoma that has progressed despite prior combination systemic chemotherapy. Pegylated liposomal doxorubicin has become a first-line standard of care for advanced AIDS-related Kaposi sarcoma, with high response rates and manageable toxicity.
Celdoxome pegylated liposomal has fundamentally different pharmacokinetic properties than conventional doxorubicin hydrochloride or other liposomal doxorubicin products. The dosing schedules, maximum recommended doses, and side effect profiles are distinctly different. These products must NEVER be substituted for one another on a milligram-for-milligram basis. Always verify that the correct doxorubicin formulation is being prescribed and dispensed.
What Should You Know Before Taking Celdoxome Pegylated Liposomal?
Contraindications
There are specific medical situations in which Celdoxome pegylated liposomal must not be used. Understanding these absolute contraindications is critical for patient safety and appropriate treatment selection.
- Hypersensitivity: Do not receive Celdoxome pegylated liposomal if you have a known allergy to doxorubicin hydrochloride, any other anthracycline, or any of the excipients in the formulation, including the liposomal components. Severe allergic reactions including anaphylaxis have been reported with pegylated liposomal doxorubicin.
- Breastfeeding: Treatment with Celdoxome pegylated liposomal is contraindicated during breastfeeding, as doxorubicin and its metabolites may be excreted in breast milk and could cause serious harm to the nursing infant.
Warnings and Precautions
All patients must have their cardiac function assessed before starting Celdoxome pegylated liposomal, using echocardiography or multigated acquisition (MUGA) scan. Monitoring should continue regularly throughout treatment. Although the risk of cardiotoxicity is lower than with conventional doxorubicin, cumulative anthracycline exposure can cause irreversible congestive heart failure. Particular caution is warranted in patients with prior anthracycline use, pre-existing cardiac disease, concurrent cardiotoxic medications, or prior mediastinal radiation therapy.
Before and during treatment with Celdoxome pegylated liposomal, your doctor should be informed about any of the following conditions or circumstances:
- Liver impairment: Doxorubicin is extensively metabolized by the liver and excreted in bile. Patients with impaired liver function may have increased exposure to doxorubicin, requiring dose reductions. Liver function tests should be performed before each dose, and the dose should be reduced if bilirubin levels are elevated. In patients with severe hepatic impairment, use is generally not recommended.
- Myelosuppression: Celdoxome pegylated liposomal can cause severe bone marrow suppression, including neutropenia, thrombocytopenia, and anemia. Complete blood counts should be monitored before each dose. Treatment may need to be delayed or doses reduced if blood counts are too low. Patients with pre-existing myelosuppression from prior chemotherapy or radiation may be at increased risk.
- Infusion-related reactions: Infusion-related reactions including flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest or throat, and hypotension can occur, particularly during the first infusion. These reactions are thought to be related to the liposomal component. The initial infusion rate should be limited to 1 mg/minute to minimize this risk, and appropriate resuscitation equipment should be available.
- Secondary malignancies: Treatment with topoisomerase II inhibitors including doxorubicin has been associated with an increased risk of secondary acute myeloid leukemia and myelodysplastic syndrome, typically occurring 1–3 years after treatment.
- Radiation recall: Celdoxome pegylated liposomal can cause radiation recall reactions in patients who have previously received radiation therapy. These reactions present as skin inflammation in previously irradiated areas and can be severe.
- Extravasation: Although pegylated liposomal doxorubicin is considered less of a vesicant than conventional doxorubicin, extravasation (leakage from the vein during infusion) can still cause local tissue damage. Infusions should be administered through a properly functioning intravenous line, and the infusion site should be monitored carefully.
Pregnancy and Breastfeeding
Celdoxome pegylated liposomal should not be used during pregnancy unless clearly necessary and only after careful consideration of the benefit to the mother versus the potential risk to the fetus. Doxorubicin is embryotoxic and teratogenic in animal studies. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose. Male patients must use contraception during treatment and for 6 months after the last dose. Doxorubicin may cause irreversible infertility; fertility preservation should be discussed before treatment begins.
If pregnancy occurs during treatment, the patient must be informed of the potential hazard to the fetus. Breastfeeding must be discontinued before starting Celdoxome pegylated liposomal and must not be resumed during treatment. It is not known whether doxorubicin or its metabolites are excreted in human milk, but given the potential for serious adverse effects in the breastfed infant, nursing is contraindicated.
Regarding fertility, doxorubicin is known to be mutagenic and can damage DNA in both germ cells and somatic cells. Women and men should receive counseling about fertility preservation options (such as oocyte or embryo cryopreservation for women, and sperm banking for men) before initiating treatment, particularly if future parenthood is desired. The gonadotoxic effects of doxorubicin may be permanent, and recovery of fertility after treatment cannot be guaranteed.
How Does Celdoxome Pegylated Liposomal Interact with Other Drugs?
Drug interactions with Celdoxome pegylated liposomal can be clinically significant and may require dose adjustments, enhanced monitoring, or avoidance of certain combinations. Because doxorubicin is metabolized by cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, drugs that affect these pathways can alter doxorubicin levels. Additionally, the combination with other agents that have overlapping toxicity profiles — particularly cardiotoxicity and myelosuppression — requires careful risk-benefit assessment.
Major Interactions
| Interacting Drug | Effect | Clinical Action |
|---|---|---|
| Trastuzumab | Significantly increased risk of cardiotoxicity; combined anthracycline-trastuzumab cardiac damage can be severe and irreversible | Avoid concurrent use; if sequential use, allow washout period of at least 7 months; monitor cardiac function closely |
| Cyclophosphamide | Enhanced cardiotoxicity and increased myelosuppression; may also potentiate hemorrhagic cystitis | Monitor cardiac function and blood counts closely; consider dose adjustments |
| Ciclosporin | Increased doxorubicin plasma concentrations due to inhibition of CYP3A4 and P-glycoprotein; increased toxicity risk | Consider dose reduction of doxorubicin; monitor closely for toxicity |
| Live vaccines | Risk of severe, potentially fatal vaccine-related infections due to immunosuppression | Avoid all live vaccines during treatment and for at least 6 months after completion |
| Paclitaxel | May increase doxorubicin plasma levels if given before doxorubicin; increased risk of neutropenia and stomatitis | Administer doxorubicin before paclitaxel when used sequentially; monitor blood counts |
Minor Interactions
| Interacting Drug | Effect | Clinical Action |
|---|---|---|
| CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) | May increase doxorubicin levels and toxicity | Monitor for increased side effects; consider dose adjustment |
| CYP3A4 inducers (e.g., rifampicin, phenytoin) | May decrease doxorubicin levels and reduce efficacy | Avoid concurrent strong CYP3A4 inducers if possible; monitor treatment response |
| Digoxin | Chemotherapy may reduce absorption of oral digoxin | Monitor digoxin levels; adjust dose as needed |
| Calcium channel blockers | May enhance doxorubicin accumulation in cells; potential increased toxicity | Monitor closely during concurrent use |
This list of interactions is not exhaustive. Patients should inform their oncologist, pharmacist, and all treating healthcare providers about every medication they are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. Some herbal products (such as St. John’s wort) are potent CYP3A4 inducers and can significantly reduce the effectiveness of doxorubicin. Grapefruit juice should also be avoided as it can inhibit CYP3A4 and increase drug levels.
What Is the Correct Dosage of Celdoxome Pegylated Liposomal?
Celdoxome pegylated liposomal must only be administered under the supervision of an oncologist experienced in cytotoxic chemotherapy, in a hospital or clinical setting equipped to handle potential complications. The dose is individualized based on body surface area (BSA) and varies according to the specific cancer being treated. It is critical to note that the dosing of pegylated liposomal doxorubicin is NOT the same as conventional doxorubicin — these formulations must never be substituted on a milligram-for-milligram basis.
Adults
| Indication | Dose | Schedule | Notes |
|---|---|---|---|
| Breast cancer | 50 mg/m² | Every 4 weeks | Continue until disease progression or unacceptable toxicity |
| Ovarian cancer | 50 mg/m² | Every 4 weeks | Treat for minimum 4 cycles; continue as long as patient benefits |
| Multiple myeloma | 30 mg/m² | Day 4, every 3 weeks | Given with bortezomib (1.3 mg/m² days 1, 4, 8, 11); treat for up to 8 cycles |
| Kaposi sarcoma | 20 mg/m² | Every 2–3 weeks | Continue for 2–3 months or until disease progression; avoid intervals less than 10 days |
Children
The safety and efficacy of Celdoxome pegylated liposomal in children and adolescents under 18 years of age have not been established. There are insufficient data to recommend a dose in the pediatric population. Use in children should only be considered in exceptional circumstances within clinical trial settings, as the pharmacokinetics and safety profile may differ from adults.
Elderly Patients
No specific dose adjustment is routinely required for elderly patients based solely on age. However, elderly patients may have reduced hepatic and renal function, lower bone marrow reserve, and a higher prevalence of comorbidities including cardiac disease. Careful assessment of liver function, cardiac function, and baseline blood counts is essential before initiating therapy. Starting at the lower end of the dosing range and careful monitoring may be prudent. Clinical trials of pegylated liposomal doxorubicin have included a substantial proportion of patients over 65 years of age, and no overall differences in safety or efficacy were observed compared with younger patients, although greater sensitivity in some older individuals cannot be ruled out.
Dose Adjustments
Dose modifications may be required in the following circumstances:
- Hepatic impairment: If bilirubin is 1.2–3.0 mg/dL, reduce the dose by 25%. If bilirubin is above 3.0 mg/dL, reduce the dose by 50%. Treatment should not be initiated in patients with severe hepatic impairment.
- Hand-foot syndrome (Grade 2–3): Delay treatment for up to 2 weeks. For Grade 3 (blistering, ulceration), reduce dose by 25% or discontinue.
- Stomatitis (Grade 2–4): Delay treatment for up to 2 weeks; for persistent or severe stomatitis, reduce dose by 25% or discontinue.
- Hematologic toxicity (Grade 4 neutropenia or thrombocytopenia): Delay treatment until recovery; consider dose reduction by 25% or growth factor support for subsequent cycles.
Missed Dose
Since Celdoxome pegylated liposomal is administered in a hospital or clinic setting by healthcare professionals, missed doses are managed by the oncology team. If a scheduled infusion is missed or delayed (due to toxicity, scheduling issues, or other medical reasons), the treatment team will determine the appropriate timing for the next dose. The treatment cycle is generally resumed as soon as the patient has recovered from any side effects that caused the delay. There is no need to “double up” on doses — each infusion is given at the standard prescribed dose.
Overdose
Overdose with Celdoxome pegylated liposomal can cause severe, life-threatening toxicity. Acute overdose would be expected to worsen the known adverse effects: severe myelosuppression (particularly neutropenia and thrombocytopenia), severe mucositis, severe hand-foot syndrome, and cardiac damage. There is no specific antidote. Treatment is supportive and symptomatic, including hospitalization, antibiotic therapy for infections, platelet and blood transfusions, and close cardiac monitoring. The maximal cumulative lifetime dose of doxorubicin (from all formulations combined) should generally not exceed 550 mg/m² (or 400 mg/m² in patients with prior mediastinal irradiation or concurrent cardiotoxic therapy).
What Are the Side Effects of Celdoxome Pegylated Liposomal?
Like all chemotherapy medications, Celdoxome pegylated liposomal can cause side effects. The side effect profile of pegylated liposomal doxorubicin differs meaningfully from conventional doxorubicin. Notably, nausea, vomiting, and alopecia (hair loss) are less frequent and less severe with the liposomal formulation. However, hand-foot syndrome and stomatitis (mouth sores) are more prominent. The frequency and severity of side effects vary depending on the dose, treatment schedule, underlying cancer type, and individual patient factors.
Not everyone experiences all of these side effects. Many side effects are manageable with appropriate supportive care, dose modifications, and preventive measures. You should report any new or worsening symptoms to your healthcare team promptly, as early intervention can prevent escalation to more serious toxicity.
Very Common
Affects more than 1 in 10 patients
- Palmar-plantar erythrodysesthesia (hand-foot syndrome) — redness, swelling, pain, tingling, or peeling of the skin on palms and soles
- Nausea
- Fatigue and asthenia (weakness)
- Stomatitis and mucositis (mouth sores, inflammation of the mucous membranes)
- Neutropenia (low white blood cell count, increasing infection risk)
- Anemia (low red blood cell count)
- Thrombocytopenia (low platelet count, increasing bleeding risk)
- Leukopenia (low total white blood cells)
- Diarrhea
- Rash
- Vomiting
- Decreased appetite
- Constipation
Common
Affects 1 in 10 to 1 in 100 patients
- Oral candidiasis (thrush)
- Herpes zoster (shingles)
- Urinary tract infections
- Folliculitis
- Peripheral neuropathy (numbness or tingling in hands/feet)
- Headache
- Dizziness
- Insomnia
- Alopecia (hair loss, typically mild)
- Dry skin and pruritus (itching)
- Skin discoloration and hyperpigmentation
- Abdominal pain
- Dyspepsia (indigestion)
- Fever (pyrexia)
- Edema (swelling)
- Musculoskeletal pain
- Dyspnea (shortness of breath)
- Cough
- Epistaxis (nosebleeds)
- Weight loss
- Elevated liver enzymes
- Dehydration
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Congestive heart failure (cardiomyopathy)
- Deep vein thrombosis
- Pulmonary embolism
- Tachycardia (rapid heartbeat)
- Left ventricular dysfunction
- Secondary acute myeloid leukemia / myelodysplastic syndrome
- Tumor lysis syndrome
- Anaphylactic reaction
- Pneumonitis
- Jaundice
Rare
Affects fewer than 1 in 1,000 patients
- Severe cardiac failure with fatal outcome
- Severe anaphylaxis
- Radiation recall dermatitis
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Erythema multiforme
Hand-foot syndrome is the most characteristic side effect of Celdoxome pegylated liposomal. Patients can take several measures to reduce its severity: keep hands and feet cool (avoid hot water), use thick emollient creams regularly, avoid tight-fitting shoes and gloves, minimize friction on hands and feet, and avoid prolonged standing or vigorous exercise that increases blood flow to extremities. Cooling hands and feet during the infusion with ice packs may also help. If symptoms become severe (blistering, ulceration, significant pain), notify your healthcare team immediately, as dose reduction or treatment delay may be necessary.
How Should You Store Celdoxome Pegylated Liposomal?
Celdoxome pegylated liposomal is a hospital-use medication, and proper storage is critical to maintain the stability and integrity of the liposomal formulation. Incorrect storage can compromise the liposomal structure, potentially altering the drug’s release characteristics and safety profile.
- Temperature: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If the product is accidentally frozen, it must be discarded as freezing can irreversibly damage the liposomal structure.
- Light protection: Keep the vials in the original outer carton to protect from light. The liposomal formulation may be sensitive to light-induced degradation.
- After dilution: Once diluted for infusion in 5% glucose solution, chemical and physical in-use stability has been demonstrated for up to 24 hours at 2–8°C. From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the hospital pharmacy.
- Do not use after the expiry date printed on the carton and vial label.
- Disposal: Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic agents. The product should be handled using appropriate chemotherapy safety precautions, including use of gloves, gowns, and eye protection.
Patients do not typically need to store this medication at home, as it is prepared and administered in a hospital or clinic by trained healthcare professionals. If you have any questions about the handling of your treatment, speak with your healthcare team or hospital pharmacist.
What Does Celdoxome Pegylated Liposomal Contain?
Each milliliter of Celdoxome pegylated liposomal concentrate for dispersion for infusion contains 2 mg of doxorubicin hydrochloride as the active ingredient. The product is available in two vial sizes:
- 10 mL vial: contains 20 mg doxorubicin hydrochloride
- 25 mL vial: contains 50 mg doxorubicin hydrochloride
The doxorubicin is encapsulated within STEALTH liposomes, which are composed of the following lipid components:
- N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG-2000-DSPE): This is the PEG-modified phospholipid that gives the liposomes their “stealth” properties, reducing immune system recognition and extending circulation time.
- Fully hydrogenated soy phosphatidylcholine (HSPC): A major structural component of the liposomal bilayer membrane.
- Cholesterol: Stabilizes the liposomal membrane and controls permeability.
Additional excipients include ammonium sulfate, sucrose (used as a cryoprotectant and tonicity agent), histidine (as a buffer), water for injections, and hydrochloric acid and/or sodium hydroxide for pH adjustment. The resulting product has a pH of approximately 6.5.
The concentrate for dispersion for infusion is a sterile, translucent red dispersion. Before administration, it must be diluted in 5% glucose (dextrose) solution for infusion. It must NOT be diluted in other solutions, and must NOT be mixed with bacteriostatic agents. The product does not contain any preservatives. Each vial is for single use only; any unused portion must be discarded.
Frequently Asked Questions
Celdoxome pegylated liposomal contains doxorubicin enclosed in tiny PEG-coated liposomes (fat-based nanoparticles), which dramatically changes how the drug behaves in the body. The liposomal formulation circulates in the blood for much longer (half-life of about 55 hours versus about 5 hours for conventional doxorubicin) and accumulates preferentially in tumor tissue. This results in significantly less cardiotoxicity (heart damage), less nausea and vomiting, and less hair loss compared with conventional doxorubicin. However, hand-foot syndrome and mouth sores are more common. The dosing regimens are completely different, and the two formulations must never be substituted for each other.
Hair loss (alopecia) can occur with Celdoxome pegylated liposomal, but it is significantly less common and less severe than with conventional doxorubicin. When it does occur, it is usually mild (thinning rather than complete baldness) and is generally reversible after treatment is completed. This is one of the key advantages of the liposomal formulation — the liposomes reduce the exposure of hair follicles to high concentrations of free doxorubicin. However, individual responses vary, and some patients may experience more noticeable hair thinning.
Treatment duration varies by indication. For breast cancer and ovarian cancer, treatment typically continues until the disease progresses or unacceptable side effects occur, which may be several months to over a year. For multiple myeloma (with bortezomib), treatment is usually given for up to 8 three-week cycles. For Kaposi sarcoma, treatment typically lasts 2–3 months but may continue longer if the patient is benefiting. Your oncologist will determine the optimal treatment duration based on your response and tolerance.
One of the primary advantages of Celdoxome pegylated liposomal over conventional doxorubicin is its significantly reduced risk of cardiotoxicity. In fact, in breast cancer it is specifically indicated for patients at increased cardiac risk. However, all patients receiving any doxorubicin-containing product must have their heart function assessed before starting treatment, and regular cardiac monitoring is required during therapy. The risk of cardiac damage increases with cumulative doxorubicin dose. Your cardiologist and oncologist should collaborate to determine whether Celdoxome pegylated liposomal is appropriate for your specific cardiac situation.
If you develop severe hand-foot syndrome (blistering, ulceration, or significant pain that interferes with daily activities), contact your oncology team immediately. Treatment may need to be delayed until symptoms improve, and your dose may be reduced for subsequent cycles. In the meantime, keep affected areas cool, apply thick emollient creams frequently, avoid hot water, wear loose-fitting shoes and soft cotton gloves at night, and avoid activities that cause friction on hands and feet. Over-the-counter pain relievers may help manage discomfort. Prevention strategies include cooling hands and feet during infusions and applying moisturizer proactively.
All information is based on international medical guidelines and peer-reviewed research: the EMA-approved Summary of Product Characteristics (SmPC) for pegylated liposomal doxorubicin products, ESMO Clinical Practice Guidelines for breast and ovarian cancer, NCCN Clinical Practice Guidelines in Oncology, WHO Model List of Essential Medicines, and published randomized controlled trials including the landmark studies establishing the efficacy and safety of pegylated liposomal doxorubicin across its approved indications. All medical claims follow evidence level 1A standards based on systematic reviews and randomized controlled trials.
References
- European Medicines Agency (EMA). Celdoxome pegylated liposomal – Summary of Product Characteristics. EMA Product Information. Updated 2025.
- O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449.
- Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–3322.
- Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892–3901.
- Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445–2451.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- European Society for Medical Oncology (ESMO). ESMO Clinical Practice Guidelines: Breast Cancer. Updated 2024.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Ovarian Cancer, and Multiple Myeloma. Version 2025.
- Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987–992.
- Barenholz Y. Doxil – the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in oncology, pharmacology, and cancer therapeutics.
Medical Content
iMedic Oncology Editorial Team – specialist physicians in medical oncology and hematology with clinical experience in cancer chemotherapy
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, ESMO, and NCCN guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and liposomal drug delivery systems
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.